|
Intra-arterial
Cereport (RMP-7) and carboplatin: a dose escalation study for recurrent
malignant gliomas
Cloughesy
TF, Black KL, Gobin YP, Farahani K, Nelson G, Villablanca P, Kabbinavar F,
Vineula F, Wortel CH
Department
of Neurology, and Jonsson Comprehensive Cancer Center, University of California,
Los Angeles School of Medicine, USA.
Objective.
Animal and human studies have shown increased delivery of radiolabeled compounds
across the blood-brain-tumor barrier using intra-arterial (IA) Cereport (RMP-7;
Alkermes Inc., Cambridge, MA) with a radiolabeled tracer.
This present study assesses the safety, tolerance, and preliminary efficacy of
the IA administration of carboplatin with Cereport.
Methods.
An open-label dose escalation study of IA Cereport (10-300 ng/kg) with 100 mg of
IA carboplatin was conducted in 11 patients with recurrent malignant gliomas and
1 patient treated adjuvantly after radiation therapy.
Tumor size and laboratory and clinical statuses were assessed.
Results.
Adverse events were mainly neurological in nature and corresponded to the
anatomic location of the tumor. Karnofsky performance scale scores did not
decline, overall, for those patients who had tumor response.
Tumor shrinkage was observed in three of six evaluable patients who received a
dose of 300 ng/kg with durable responses of 60, 64, and 106+ weeks.
Conclusion.
Previous studies have demonstrated increased permeability in human gliomas using
IA Cereport.
This study demonstrates durable imaging responses using 100 mg of IA carboplatin
in combination with Cereport.
The drug combination in this patient population seems to be safe and acceptable,
providing a novel means of antitumor dose intensification.
PMID:
9932880 [PubMed - indexed for MEDLINE]
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9932880&dopt=Abstract |
